Novartis Pipeline

Benefiting from our continued focus on innovation, Novartis has one of the industry’s most competitive pipelines. Many of these projects, which include new molecular entities as well as additional indications and different formulations for marketed products, are for medicines that could significantly advance treatment standards for patients worldwide. This table provides an overview of selected projects in development. Please note: the Novartis Pipeline data is updated quarterly.

Download the Novartis pipeline as of December 31, 2022 (PDF 0.1 MB)

Showing 152 results
  • NGI226
    NGI226
    Tendinopathy
    Immunology Phase 1
    Lead Indication
  • NIO752
    NIO752
    Progressive supranuclear palsy
    Neuroscience Phase 1 Tau antagonist
    Lead Indication
  • NIR178
    NIR178, spartalizumab
    Cancers
    Solid Tumors Phase 2 Ad2AR Inhibitor, PD1 Inhibitor (Anti-PD-1 monoclonal antibody)
    Lead Indication
  • NIS793
    NIS793
    1L Metastatic pancreatic ductal adenocarcinoma
    Solid Tumors Phase 3 2025 TGFB1 inhibitor
    Lead Indication
  • NIS793
    NIS793
    Colorectal cancer (Combos)
    Solid Tumors Phase 1 TGFB1 inhibitor
  • NIS793
    NIS793, spartalizumab
    1L metastatic colorectal cancer
    Solid Tumors Phase 2 TGFB1 inhibitor
  • NIZ985
    NIZ985, spartalizumab
    Solid tumors
    Solid Tumors Phase 1 IL-15 Agonist
    Lead Indication
  • NZV930
    NZV930, spartalizumab, NIR178
    Solid tumors
    Solid Tumors Phase 1 CD73 Antagonist
    Lead Indication
  • OAV101
    AVXS-101
    Spinal muscular atrophy (SMA) IT administration
    Neuroscience Phase 3 2025 Survival motor neuron (SMN1) gene replacement therapy
    Supplementary Indication
  • OMB157
    Kesimpta®
    Multiple sclerosis, pediatrics
    Neuroscience Phase 3 >=2026 CD20 Antagonist
    Supplementary Indication
  • PHE885
    PHE885
    4L multiple myeloma
    Hematology Phase 2 BCMA cell therapy
    Lead Indication
  • PIT565
    PIT565
    B-cell malignancies
    Hematology Phase 1
    Lead Indication
  • PKC412
    Rydapt®
    Acute myeloid leukemia, pediatrics
    Hematology Phase 2 >=2026 Multi-targeted kinase inhibitor
    Supplementary Indication
  • PPY988
    PPY988
    Geographic atrophy
    Ophthalmology Phase 2 >=2026 Gene therapy - Complement factor I modulation
    Lead Indication
  • QGE031
    ligelizumab
    Food allergy
    Immunology Phase 3 >=2026 IgE Inhibitor (High-affinity anti-IgE monoclonal antibody)
    Lead Indication
  • QMF149
    Atectura®
    Pediatric Asthma
    Global Health Phase 2 >=2026 Indacaterol acetate +mometasone furoate
    Supplementary Indication
  • QUC398
    QUC398
    Osteoarthritis
    Immunology Phase 2 ADAMTS5 inhibitor
    Lead Indication
  • RTH258
    Beovu®
    Diabetic Retinopathy
    Ophthalmology Phase 3 2025 VEGF inhibitor
    Supplementary Indication
  • SAF312
    libvatrep
    Chronic ocular surface pain (COSP)
    Ophthalmology Phase 2 >=2026 TRPV1 antagonist
    Lead Indication
  • SEG101
    Adakveo®
    Ped sickle cell anaemia with crisis, pediatrics
    Global Health Phase 2 P-selectin inhibitor
    Supplementary Indication
Legend

Combination abbreviations:
fulv    fulvestrant
tmx    tamoxifen
gsn    goserelin
NSAI  Non-steroidal aromatase inhibitor
Taf     Tafinlar® (dabrafenib)
Mek   Mekinist® (trametinib)

a    EU filing, approved in US.
b    US filing, approved in EU.
c    US filing, submitted in EU.
d    US pending submission, approved in EU
e    EU filing, submitted in US.

Disclaimer

This information was factually accurate on the date it was published. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date. For the latest information on the Novartis' pipeline, readers should visit the News and Investors sections of our website. This information constitutes forward-looking statements relating to Novartis AG's business, including express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products. Such forward-looking statements reflect the current views of Novartis AG regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for existing products in any market, or that such products will achieve any particular revenue levels.

In particular, management's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally; the Novartis Group's ability to obtain or maintain patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.